Thursday, March 16, 2017 2:15:53 AM
1) LF trial start will trigger NVS option exercise in Q2
2) Enough cash until end of 2019
3) Announcement of new pipeline developemnt beyond Emricasan later in 2017
4) LF trial will focus not only on decompensated patients with MELD score at or above 15 (the subset where it showed significant MELD score reduction in ph2a). This trial is the only existing trial on this very sick population who face either a transplant (only a few have access) or death
5) LF ph2b trial could either be used as base for ph3 with clinical endpoints or for AA using surrogate endpoint(s, ie MELD score). By adding 4&5 good chance of an AA then
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM